Comparing the Effects of Glucagon-Like Peptide-1 Receptor Agonists on Cardiovascular Events to Metformin in Patients With Polycystic Ovary Syndrome: A Real-World Multicenter Cohort Study Across the United States [ID 1078]
Abstract
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP1RA), known for their weight-loss and antidiabetic effects, have been recommended by the American Diabetes Association as a first-line treatment for type 2 diabetes mellitus due to their cardiovascular benefits. However, the effects of GLP1RA on polycystic ovary syndrome (PCOS) remain unclear. The study aims to compare the effects of GLP1RA on cardiovascular events in PCOS to metformin, an active comparator with known cardiometabolic benefits. METHODS: We included females aged 12 or older who were diagnosed with PCOS and had at least two prescriptions of GLP1RA or metformin from May 1, 2005 (first GLP1RA approval), to December 31, 2021, from the TriNetX database with 60 or more U.S. health care institutions. After 1:1 propensity score matching on body mass index, comorbidities, lipid profiles, Hb A1C, and medications, hazard ratios (HRs) and 95% CIs for outcomes were calculated using the Cox regression model. Patients were observed for 3 years after drug initiation and censored if: 1) cardiovascular event diagnosis; 2) study end date: May 17, 2024; 3) loss to follow-up, whichever occurred first. RESULTS: Compared to metformin, GLP1RA was associated with significantly reduced arrhythmia (HR 0.83; 95% CI, 0.75–0.91) and thrombotic disorders (HR 0.78; 95% CI, 0.68–0.90). GLP1RA was associated with a lower, although nonsignificant, risk of cerebrovascular events (HR 0.88; 95% CI, 0.77–1.01), inflammatory heart disease…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.